RGS22 Inhibitors

RGS22 inhibitors represent a category of chemical entities that either directly or predominantly indirectly influence the activity of the RGS22 protein. Their principal mechanism relies on disrupting the G protein-coupled receptor (GPCR) signaling pathway. Pertussis Toxin, for example, interferes with Gi/o protein signaling, which can affect the regulatory pathways associated with RGS22. Similarly, YM-254890 and NF023 specifically target Gq and Gα proteins, respectively, modulating the signaling landscape that RGS22 may act upon.

The Gβγ signaling arm of the GPCR pathway can be impacted by Gallein and M119, offering an alternative route to influence RGS22 activity. Meanwhile, SCH-202676 disrupts ligand binding to GPCRs, which leads to downstream effects that can affect the function or regulatory role of RGS proteins. A broader approach includes the use of Suramin, a general G protein antagonist, which casts a wide net over G protein-mediated pathways, including those regulated by RGS22. Another layer of regulation is provided by chemicals like Chelerythrine Chloride, U73122, SQ22,536, and KT5720, which target intermediary molecules or enzymes, such as PKC, phospholipase C, adenylate cyclase, and PKA.